Sign in or create an account to add this stock to your watchlist.
About Teligent (NASDAQ:TLGT)
Teligent, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It also develops, manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The company's products are used in various applications that range from cosmetics and cosmeceuticals to the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. In addition, it offers contract manufacturing and formulation services. Teligent, Inc. sells its products through national chain drug stores, drug wholesalers, distributors, and group purchasing organizations. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015. Teligent, Inc. was founded in 1977 and is based in Buena, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TLGT
CUSIPN/A
Phone856-697-1441
Debt
Debt-to-Equity Ratio3.07
Current Ratio2.73
Quick Ratio1.69
Price-To-Earnings
Trailing P/E Ratio-14.58
Forward P/E Ratio-46.17
P/E GrowthN/A
Sales & Book Value
Annual Sales$67.25 million
Price / Sales2.20
Cash Flow$0.0722 per share
Price / Cash38.38
Book Value$0.75 per share
Price / Book3.69
Profitability
EPS (Most Recent Fiscal Year)($0.19)
Net Income$-15,190,000.00
Net Margins-28.98%
Return on Equity-27.25%
Return on Assets-6.94%
Miscellaneous
Employees183
Outstanding Shares53,510,000
Teligent (NASDAQ:TLGT) Frequently Asked Questions
What is Teligent's stock symbol?
Teligent trades on the NASDAQ under the ticker symbol "TLGT."
How were Teligent's earnings last quarter?
Teligent (NASDAQ:TLGT) announced its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.01. The company had revenue of $14.55 million for the quarter, compared to the consensus estimate of $15.62 million. Teligent had a negative net margin of 28.98% and a negative return on equity of 27.25%. View Teligent's Earnings History.
What price target have analysts set for TLGT?
3 equities research analysts have issued 1 year price targets for Teligent's stock. Their forecasts range from $4.00 to $9.00. On average, they anticipate Teligent's share price to reach $7.00 in the next year. View Analyst Ratings for Teligent.
What are Wall Street analysts saying about Teligent stock?
Here are some recent quotes from research analysts about Teligent stock:
- 1. According to Zacks Investment Research, "Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey. " (5/10/2018)
- 2. Canaccord Genuity analysts commented, "We’re confident that the company’s revised expectations are achievable and delays at the agency will resolve in short order. We continue to view Teligent as a uniquely positioned generic company poised for meaningful growth over the next several years. We maintain our BUY rating and $11 price target on TLGT shares. Light revenue due to lidocaine ointment and Zantac; lidocaine solution a surprising star in the report. Teligent’s 2Q/17 revenue was $18.4 mm compared to our $19mm estimate and $20.3 mm consensus. In our post-launch thoughts, we believed investors were expecting a light quarter and potential downward revision to 2H/17 expectations. Adjusted loss per share was ($0.01) compared to our EPS estimate of +$0.01 and consensus of +$0.02. Teligent saw incremental competition and double-digit price erosion on lidocaine ointment and a return of a competitor on Zantac injection coupled with lower-than-expected Zantac utilization rates due to recent inventory shortages that changed physician use patterns." (8/8/2017)
Are investors shorting Teligent?
Teligent saw a increase in short interest in May. As of May 15th, there was short interest totalling 11,348,274 shares, an increase of 49.8% from the April 30th total of 7,576,860 shares. Based on an average daily trading volume, of 726,537 shares, the short-interest ratio is presently 15.6 days. Currently, 26.3% of the shares of the stock are short sold.
Who are some of Teligent's key competitors?
Some companies that are related to Teligent include Aclaris Therapeutics (ACRS), Akebia Therapeutics (AKBA), Prothena (PRTA), Stemline Therapeutics (STML), CannTrust (CNTTF), Kura Oncology (KURA), Cara Therapeutics (CARA), Progenics Pharmaceuticals (PGNX), Achaogen (AKAO), TIGENIX/S (TIG), Evolus (EOLS), Mersana Therapeutics (MRSN), Evelo Biosciences (EVLO), Zymeworks (ZYME) and Insys Therapeutics (INSY).
Who are Teligent's key executives?
Teligent's management team includes the folowing people:
- Mr. Jason Grenfell-Gardner M.B.A., M.B.A, Pres, CEO & Director (Age 43)
- Mr. Stephen Richardson, Chief Scientific Officer (Age 52)
- Mr. Martin Wilson, Gen. Counsel (Age 41)
- Mr. Damian Finio, Corp. Sec. & CFO (Age 48)
- Ms. Nadya Lawrence, Sr. VP of Technical Services (Age 49)
Has Teligent been receiving favorable news coverage?
News coverage about TLGT stock has trended somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Teligent earned a news sentiment score of 0.13 on Accern's scale. They also assigned media coverage about the company an impact score of 43.79 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Teligent's major shareholders?
Teligent's stock is owned by many different of retail and institutional investors. Top institutional investors include venBio Select Advisor LLC (9.90%), Elk Creek Partners LLC (6.64%), BlackRock Inc. (6.37%), Prosight Management LP (4.62%), Eversept Partners LLC (2.90%) and First Light Asset Management LLC (2.06%). Company insiders that own Teligent stock include Carole Ben-Maimon, Jenniffer Collins, Stephen Richardson and Steven H Koehler. View Institutional Ownership Trends for Teligent.
Which major investors are selling Teligent stock?
TLGT stock was sold by a variety of institutional investors in the last quarter, including Stifel Financial Corp, First Light Asset Management LLC, Eversept Partners LLC, GSA Capital Partners LLP and BlackRock Inc.. View Insider Buying and Selling for Teligent.
Which major investors are buying Teligent stock?
TLGT stock was purchased by a variety of institutional investors in the last quarter, including Prosight Management LP, Elk Creek Partners LLC, Algert Global LLC, venBio Select Advisor LLC, A.R.T. Advisors LLC, NJ State Employees Deferred Compensation Plan, Citadel Advisors LLC and Spark Investment Management LLC. Company insiders that have bought Teligent stock in the last two years include Carole Ben-Maimon, Jenniffer Collins, Stephen Richardson and Steven H Koehler. View Insider Buying and Selling for Teligent.
How do I buy shares of Teligent?
Shares of TLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Teligent's stock price today?
One share of TLGT stock can currently be purchased for approximately $2.77.
How big of a company is Teligent?
Teligent has a market capitalization of $148.23 million and generates $67.25 million in revenue each year. The company earns $-15,190,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Teligent employs 183 workers across the globe.
How can I contact Teligent?
Teligent's mailing address is 105 LINCOLN AVENUE, BUENA NJ, 08310. The company can be reached via phone at 856-697-1441 or via email at [email protected]
MarketBeat Community Rating for Teligent (TLGT)
MarketBeat's community ratings are surveys of what our community members think about Teligent and other stocks. Vote "Outperform" if you believe TLGT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TLGT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Teligent (NASDAQ:TLGT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Teligent in the last 12 months. Their average twelve-month price target is $7.00, suggesting that the stock has a possible upside of 152.71%. The high price target for TLGT is $9.00 and the low price target for TLGT is $4.00. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.33 | 2.33 | 2.33 | 2.33 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $7.00 | $7.00 | $7.00 | $7.3333 |
| Price Target Upside: | 152.71% upside | 182.26% upside | 83.25% upside | 39.68% upside |
Teligent (NASDAQ:TLGT) Consensus Price Target History
Teligent (NASDAQ:TLGT) Analyst Ratings History
Show:
(Data available from 5/27/2016 forward)
Teligent (NASDAQ:TLGT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Teligent (NASDAQ TLGT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 22.80%
Institutional Ownership Percentage: 62.11%
Teligent (NASDAQ TLGT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/13/2017 | Carole Ben-Maimon | Director | Buy | 5,000 | $3.48 | $17,400.00 | 2,400 |  |
| 11/10/2017 | Steven H Koehler | Director | Buy | 5,000 | $3.62 | $18,100.00 | 1,800 | |
| 11/9/2017 | Stephen Richardson | Insider | Buy | 6,410 | $3.13 | $20,063.30 | 14,744 | |
| 11/8/2017 | Jenniffer Collins | CFO | Buy | 7,000 | $3.04 | $21,280.00 | 19,206 | |
| 3/11/2016 | James C Gale | Director | Buy | 15,000 | $4.91 | $73,650.00 | 39,624 | |
| 3/11/2016 | Jason Grenfell-Gardner | CEO | Buy | 10,500 | $4.82 | $50,610.00 | 250,207 | |
(Data available from 1/1/2013 forward)
Teligent (NASDAQ TLGT) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Teligent (TLGT) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 27 at 1:36 AM |
| Teligent (TLGT) Sees Large Increase in Short Interest
www.americanbankingnews.com - May 26 at 1:30 AM |
| $16.83 Million in Sales Expected for Teligent (TLGT) This Quarter
www.americanbankingnews.com - May 22 at 1:54 AM |
| Teligent (TLGT) Expected to Announce Earnings of -$0.01 Per Share
www.americanbankingnews.com - May 20 at 11:14 PM |
| Teligent (TLGT) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 10 at 1:02 PM |
 | Edited Transcript of TLGT earnings conference call or presentation 8-May-18 12:30pm GMT
finance.yahoo.com - May 10 at 9:30 AM |
| Teligent (TLGT) Given a $4.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - May 9 at 6:20 PM |
| Teligent (TLGT) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - May 9 at 1:43 PM |
 | Teligent, Inc. to Present at Deutsche Bank’s 43rd Annual Health Care Conference on Tuesday, May 8,
www.nasdaq.com - May 8 at 9:12 AM |
| Teligent, Inc. to Reschedule Conference Call for First Quarter 2018 Results
www.nasdaq.com - May 8 at 9:12 AM |
 | Teligent misses by $0.01, misses on revenue
seekingalpha.com - May 8 at 9:12 AM |
| Teligent, Inc. Announces First Quarter 2018 Results
finance.yahoo.com - May 8 at 9:12 AM |
| Teligent: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 9:12 AM |
 | Teligent, Inc. to Present at Deutsche Bank's 43rd Annual Health Care Conference on Tuesday, May 8, 2018
feeds.benzinga.com - May 7 at 7:09 PM |
| Brokerages Anticipate Teligent (TLGT) Will Post Quarterly Sales of $15.62 Million
www.americanbankingnews.com - May 5 at 3:39 AM |
| Teligent (TLGT) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 4 at 12:06 AM |
| Teligent (TLGT) Expected to Post Earnings of -$0.03 Per Share
www.americanbankingnews.com - May 3 at 6:17 PM |
| Teligent (TLGT) to Release Earnings on Monday
www.americanbankingnews.com - May 2 at 8:32 PM |
| Teligent (TLGT) Lifted to Hold at ValuEngine
www.americanbankingnews.com - May 2 at 3:48 PM |
| Teligent, Inc. to Present at Deutsche Bank’s 43rd Annual Health Care Conference on Tuesday May 8, 2
www.nasdaq.com - May 2 at 9:13 AM |
| Teligent (TLGT) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - May 2 at 1:42 AM |
| Teligent, Inc. to Present at Deutsche Bank’s 43rd Annual Health Care Conference on Tuesday May 8, 2018
finance.yahoo.com - May 1 at 4:32 PM |
| Teligent down 10% on convertible debt exchange deal
seekingalpha.com - April 27 at 12:17 PM |
| Teligent, Inc. Announces Agreements to Exchange Approximately $65 million of its 3.75% Senior Convertible Notes Due 2019 for 4.75% Senior Convertible Notes Due 2023
finance.yahoo.com - April 27 at 9:47 AM |
| Teligent, Inc. to Hold Conference Call for First Quarter 2018 Results
finance.yahoo.com - April 26 at 4:35 PM |
 | Pre-Open Movers 04/18: (NBEV) (TLGT) (TXT) (EBAY) Higher; (AGLE) (CATB) (LRCX) (IBM) Lower (more...)
www.streetinsider.com - April 18 at 4:52 PM |
| $15.62 Million in Sales Expected for Teligent (TLGT) This Quarter
www.americanbankingnews.com - April 18 at 3:56 AM |
| FDA OKs Teligent's generic clobetasol cream; shares up 20% after hours
seekingalpha.com - April 17 at 5:03 PM |
| Teligent, Inc. Announces FDA Approval of Clobetasol Propionate Cream USP, 0.05%
finance.yahoo.com - April 17 at 5:03 PM |
| Teligent (TLGT) Research Coverage Started at Canaccord Genuity
www.americanbankingnews.com - April 15 at 9:43 AM |
| Teligent (TLGT) Downgraded to "Strong Sell" at BidaskClub
www.americanbankingnews.com - April 14 at 4:47 PM |
| Short Interest in Teligent (TLGT) Decreases By 19.5%
www.americanbankingnews.com - April 13 at 3:23 AM |
| Roth Capital Analysts Give Teligent (TLGT) a $9.00 Price Target
www.americanbankingnews.com - April 11 at 12:43 AM |
 | BRIEF-Teligent Files For Mixed Shelf Of Up To $50 Mln
www.reuters.com - April 7 at 9:47 AM |
| Teligent (TLGT) Reports FDA Approval of Ciclopirox Shampoo, 1%
www.streetinsider.com - April 7 at 9:47 AM |
| Teligent Inc (TLGT) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 7 at 1:29 AM |
| BRIEF-FDA Grants Teligent Approval Of Ciclopirox Shampoo, 1%
www.reuters.com - April 6 at 4:49 PM |
| Teligent, Inc. Announces FDA Approval of Ciclopirox Shampoo, 1%
finance.yahoo.com - April 6 at 4:49 PM |
| Canaccord Genuity Lowers Teligent (TLGT) to Hold
www.americanbankingnews.com - April 1 at 4:16 PM |
| Teligent Inc (TLGT) Expected to Announce Quarterly Sales of $15.62 Million
www.americanbankingnews.com - April 1 at 3:46 AM |
| -$0.03 Earnings Per Share Expected for Teligent Inc (TLGT) This Quarter
www.americanbankingnews.com - March 30 at 1:18 PM |
| Blog Exposure - FDA Approved Teligent’s Halobetasol Propionate Ointment, 0.05%
finance.yahoo.com - March 23 at 9:16 AM |
| Teligent, Inc. Announces FDA Approval of Halobetasol Propionate Ointment, 0.05%
finance.yahoo.com - March 21 at 10:23 AM |
| Teligent (TLGT) Given a $4.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - March 16 at 6:42 PM |
| Edited Transcript of TLGT earnings conference call or presentation 15-Mar-18 8:30pm GMT
finance.yahoo.com - March 16 at 5:35 PM |
| Teligent, Inc. to Host Earnings Call
finance.yahoo.com - March 15 at 5:06 PM |
| Teligent, Inc. Announces Fourth Quarter and Year End 2017 Results
finance.yahoo.com - March 15 at 5:06 PM |
| Teligent (TLGT) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - March 13 at 3:57 PM |
| Teligent Inc (TLGT) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - March 13 at 1:46 AM |
| Teligent, Inc. to Hold Conference Call for Fourth Quarter 2017 Results
finance.yahoo.com - March 12 at 5:39 PM |
Teligent (NASDAQ:TLGT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Teligent (NASDAQ:TLGT) Income Statement, Balance Sheet and Cash Flow Statement
Teligent (NASDAQ TLGT) Stock Chart for Sunday, May, 27, 2018
Loading chart…
